254 related articles for article (PubMed ID: 30636588)
1. Cytotoxic Stilbenes and Derivatives as Promising Antimitotic Leads for Cancer Therapy.
Faustino C; Francisco AP; Isca VMS; Duarte N
Curr Pharm Des; 2018; 24(36):4270-4311. PubMed ID: 30636588
[TBL] [Abstract][Full Text] [Related]
2. Combretastatin A-4 analogues as antimitotic antitumor agents.
Nam NH
Curr Med Chem; 2003 Sep; 10(17):1697-722. PubMed ID: 12871118
[TBL] [Abstract][Full Text] [Related]
3. Biological potential and structure-activity relationships of most recently developed vascular disrupting agents: an overview of new derivatives of natural combretastatin a-4.
Marrelli M; Conforti F; Statti GA; Cachet X; Michel S; Tillequin F; Menichini F
Curr Med Chem; 2011; 18(20):3035-81. PubMed ID: 21651481
[TBL] [Abstract][Full Text] [Related]
4. Combretastatins: An Overview of Structure, Probable Mechanisms of Action and Potential Applications.
Karatoprak GŞ; Küpeli Akkol E; Genç Y; Bardakci H; Yücel Ç; Sobarzo-Sánchez E
Molecules; 2020 May; 25(11):. PubMed ID: 32486408
[TBL] [Abstract][Full Text] [Related]
5. Discovery, synthesis, activities, structure-activity relationships, and clinical development of combretastatins and analogs as anticancer drugs. A comprehensive review.
Singh SB
Nat Prod Rep; 2024 Feb; 41(2):298-322. PubMed ID: 38009216
[TBL] [Abstract][Full Text] [Related]
6. Antineoplastic agents. 291. Isolation and synthesis of combretastatins A-4, A-5, and A-6(1a).
Pettit GR; Singh SB; Boyd MR; Hamel E; Pettit RK; Schmidt JM; Hogan F
J Med Chem; 1995 May; 38(10):1666-72. PubMed ID: 7752190
[TBL] [Abstract][Full Text] [Related]
7. Combretastatins: In vitro structure-activity relationship, mode of action and current clinical status.
Jaroch K; Karolak M; Górski P; Jaroch A; Krajewski A; Ilnicka A; Sloderbach A; Stefański T; Sobiak S
Pharmacol Rep; 2016 Dec; 68(6):1266-1275. PubMed ID: 27686966
[TBL] [Abstract][Full Text] [Related]
8. [Liposome formulations of combretastatin A4 and 4-arylcoumarin analog prodrugs: antitumor effect in the mouse model of breast cancer].
Mouseeva EV; Kuznetsova NR; Svirshchevskaia EV; Bovin NV; Sitnikov NC; Shavyrin AS; Beletskaia IP; Combes S; Fedorov AIu; Vodovozova EL
Biomed Khim; 2012; 58(3):326-38. PubMed ID: 22856138
[TBL] [Abstract][Full Text] [Related]
9. Tubulin-interactive stilbene derivatives as anticancer agents.
Mikstacka R; Stefański T; Różański J
Cell Mol Biol Lett; 2013 Sep; 18(3):368-97. PubMed ID: 23818224
[TBL] [Abstract][Full Text] [Related]
10. Pharmaceutical design of antimitotic agents based on combretastatins.
Hsieh HP; Liou JP; Mahindroo N
Curr Pharm Des; 2005; 11(13):1655-77. PubMed ID: 15892667
[TBL] [Abstract][Full Text] [Related]
11. Natural products as new antimitotic compounds for anticancer drug development.
Paier CRK; Maranhão SS; Carneiro TR; Lima LM; Rocha DD; Santos RDS; Farias KM; Moraes-Filho MO; Pessoa C
Clinics (Sao Paulo); 2018 Dec; 73(suppl 1):e813s. PubMed ID: 30540125
[TBL] [Abstract][Full Text] [Related]
12. The vascular targeting agent combretastatin-A4 and a novel cis-Restricted {beta}-Lactam Analogue, CA-432, induce apoptosis in human chronic myeloid leukemia cells and ex vivo patient samples including those displaying multidrug resistance.
Greene LM; Nathwani SM; Bright SA; Fayne D; Croke A; Gagliardi M; McElligott AM; O'Connor L; Carr M; Keely NO; O'Boyle NM; Carroll P; Sarkadi B; Conneally E; Lloyd DG; Lawler M; Meegan MJ; Zisterer DM
J Pharmacol Exp Ther; 2010 Nov; 335(2):302-13. PubMed ID: 20699436
[TBL] [Abstract][Full Text] [Related]
13. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
14. Combretastatin-based compounds with therapeutic characteristics: a patent review.
Nainwal LM; Alam MM; Shaquiquzzaman M; Marella A; Kamal A
Expert Opin Ther Pat; 2019 Sep; 29(9):703-731. PubMed ID: 31369715
[No Abstract] [Full Text] [Related]
15. Synthesis and evaluation of analogues of (Z)-1-(4-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)ethene as potential cytotoxic and antimitotic agents.
Cushman M; Nagarathnam D; Gopal D; He HM; Lin CM; Hamel E
J Med Chem; 1992 Jun; 35(12):2293-306. PubMed ID: 1613753
[TBL] [Abstract][Full Text] [Related]
16. p,p-Dihydroxydihydrostilbenophanes related to antimitotic combretastatins. Conformational analysis and its relationship to tubulin inhibition.
Álvarez R; López V; Mateo C; Medarde M; Peláez R
J Org Chem; 2014 Aug; 79(15):6840-57. PubMed ID: 24966024
[TBL] [Abstract][Full Text] [Related]
17. Isolation, structure, synthesis, and antimitotic properties of combretastatins B-3 and B-4 from Combretum caffrum.
Pettit GR; Singh SB; Schmidt JM; Niven ML; Hamel E; Lin CM
J Nat Prod; 1988; 51(3):517-27. PubMed ID: 3404149
[TBL] [Abstract][Full Text] [Related]
18. Interactions of tubulin with potent natural and synthetic analogs of the antimitotic agent combretastatin: a structure-activity study.
Lin CM; Singh SB; Chu PS; Dempcy RO; Schmidt JM; Pettit GR; Hamel E
Mol Pharmacol; 1988 Aug; 34(2):200-8. PubMed ID: 3412321
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and evaluation of stilbene and dihydrostilbene derivatives as potential anticancer agents that inhibit tubulin polymerization.
Cushman M; Nagarathnam D; Gopal D; Chakraborti AK; Lin CM; Hamel E
J Med Chem; 1991 Aug; 34(8):2579-88. PubMed ID: 1875350
[TBL] [Abstract][Full Text] [Related]
20. Resveratrol and other Stilbenes: Effects on Dysregulated Gene Expression in Cancers and Novel Delivery Systems.
Poltronieri P; Xu B; Giovinazzo G
Anticancer Agents Med Chem; 2021; 21(5):567-574. PubMed ID: 32628597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]